Clinical Trial Update: Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation [Phase 1]

View source ↗

Summary

This Phase 1 trial is evaluating the safety and preliminary efficacy of IBI351 in combination with chemotherapy for advanced non-squamous non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI351

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING